Abstract-Prehypertension is a major risk factor for hypertension. Blacks have more prevalent and severe hypertension than whites, but it is unknown whether progression from prehypertension is accelerated in blacks. We examined this question in a prospective cohort study of 18 865 nonhypertensive persons (5733 Key Words: prehypertension Ⅲ hypertension Ⅲ race Ⅲ black I n 1939, Robinson and Brucer 1 reported that individuals with blood pressures of 120 to 139/80 to 89 mm Hg were more likely to become hypertensive and die earlier than people with normal blood pressures Ͻ120/Ͻ80 mm Hg. They labeled this blood pressure range as prehypertension. The Joint National Committee on High Blood Pressure adopted the term prehypertension for the first time in its seventh report (JNC 7) in May 2003. As in 1939, the JNC 7 defined prehypertension by blood pressures 120 to 139/80 to 89 mm Hg. 2,3 Although prehypertension was controversial, several studies confirmed the 1939 report that prehypertension is a risk factor for hypertension and cardiovascular diseases (CVDs). 4 Among people with blood pressure (BP) 130 to 139 mm Hg systolic and/or 85 to 89 mm Hg diastolic (stage 2 prehypertension), the risk of developing hypertension is 3-fold that of normotensives with BP Ͻ120/Ͻ80 mm Hg. [5] [6] [7] The risk of CVD morbidity and mortality is Ϸ1.6-to 2.0-fold greater in stage 2 prehypertensives than normotensives, even without progression to hypertension. 7 In the United States, blacks have a higher prevalence of hypertension and associated cardiovascular and renal complications than whites. 8, 9 Moreover, even without progression to hypertension, prehypertensive blacks experience more CVD complications than whites. 10 These observations suggest that effective interventions, which lower BP in prehypertensives and retard the progression to hypertension, could potentially reduce black-white health disparities in prevalent hypertension. 3, 11 In fact, the International Society on Hypertension in Blacks consensus statement recommends comprehensive lifestyle intervention in blacks with BP Ն115/Ն75 mm Hg rather than Ն120/Ն80 mm Hg, as in JNC 7. 12 JNC 7 recommended therapeutic lifestyle change only for prehypertension in the absence of diabetes mellitus and clinical cardiovascular and renal disease. 1 Clinical efficacy
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n 1939, Robinson and Brucer 1 reported that individuals with blood pressures of 120 to 139/80 to 89 mm Hg were more likely to become hypertensive and die earlier than people with normal blood pressures Ͻ120/Ͻ80 mm Hg. They labeled this blood pressure range as prehypertension. The Joint National Committee on High Blood Pressure adopted the term prehypertension for the first time in its seventh report (JNC 7) in May 2003. As in 1939, the JNC 7 defined prehypertension by blood pressures 120 to 139/80 to 89 mm Hg. 2, 3 Although prehypertension was controversial, several studies confirmed the 1939 report that prehypertension is a risk factor for hypertension and cardiovascular diseases (CVDs). 4 Among people with blood pressure (BP) 130 to 139 mm Hg systolic and/or 85 to 89 mm Hg diastolic (stage 2 prehypertension), the risk of developing hypertension is 3-fold that of normotensives with BP Ͻ120/Ͻ80 mm Hg. [5] [6] [7] The risk of CVD morbidity and mortality is Ϸ1.6-to 2.0-fold greater in stage 2 prehypertensives than normotensives, even without progression to hypertension. 7 In the United States, blacks have a higher prevalence of hypertension and associated cardiovascular and renal complications than whites. 8, 9 Moreover, even without progression to hypertension, prehypertensive blacks experience more CVD complications than whites. 10 These observations suggest that effective interventions, which lower BP in prehypertensives and retard the progression to hypertension, could potentially reduce black-white health disparities in prevalent hypertension. 3, 11 In fact, the International Society on Hypertension in Blacks consensus statement recommends comprehensive lifestyle intervention in blacks with BP Ն115/Ն75 mm Hg rather than Ն120/Ն80 mm Hg, as in JNC 7. 12 JNC 7 recommended therapeutic lifestyle change only for prehypertension in the absence of diabetes mellitus and clinical cardiovascular and renal disease. 1 Clinical efficacy studies document that lifestyle changes, for example, the Dietary Approaches to Stop Hypertension, lower BP in nonhypertensive persons, especially blacks. 13 However, adoption of healthy nutrition and physical activity patterns are limited in the US population whose dietary patterns have become less Dietary Approaches to Stop Hypertension-like as body mass index (BMI) and prevalent obesity have risen. 14, 15 These observations suggest that adoption of lifestyle interventions is limited in the population and that a large proportion of individuals with stage 2 prehypertension progress to hypertension within 4 years. Thus, safe and effective pharmacological options emerge as a logical complement to therapeutic lifestyle change for reducing prevalent hypertension. 3 If blacks with prehypertension progress to hypertension at a faster rate than whites, then the rationale for studying pharmacological interventions in this high-risk group would be strengthened. Although several studies examined progression from prehypertension to hypertension, 5, 7, 16 none addressed differences between black and white individuals. Our study addresses that important knowledge gap.
Methods
This study used the Outpatient Quality Improvement Network Hypertension Initiative database. 17 The Outpatient Quality Improvement Network captures data on patients from the Southeast United States who are receiving health care at practices with electronic health record systems. Data collection is facilitated through a business associate agreement with each clinic. The agreement addresses the Health Insurance Portability and Accountability Act regulations and includes a provision for use of deidentified data for research. The data file includes patient demographics (age, race, and sex), visits and visit dates, vital signs, diagnoses and procedure codes, medications, and laboratory data. The source of race information retrieved from the electronic health record was not specified. This study was approved by the Medical University of South Carolina Institutional Review Board.
This study examined differences in conversion rates between non-Hispanic blacks and non-Hispanic whites in a prospective observational cohort design. Patients were selected from among 1 720 242 patients seen at participating practices between January 1, 2003, and December 31, 2007. Subjects were eligible for this study if they were 18 to 85 years old and had Ն4 visits with a valid BP measurement over a period Ն2 years.
Patients were excluded if they had initial BP values Ն140 mm Hg systolic and/or Ն90 mm Hg diastolic, a diagnosis of hypertension (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] 401 to 405), or prescription for antihypertensive medication. Persons with a history of active drug or alcohol abuse (ICD-9-CM 303 to 305), major psychiatric illness (ICD-9-CM 290 to 299), or malignancy (ICD-9-CM 140 to 208) were excluded. Persons with missing race, Hispanic ethnicity, or who did not meet inclusion criteria were excluded. Figure 1 Data analyses were conducted with SAS software package (SAS version 9.03, Cary, NC). 18 Descriptive statistics for group comparisons included t tests for continuous variables and 2 for proportions. The relationship between the dependent variable (conversion to hypertension) and various risk factors or independent variables was examined as a function of time using survival analysis. Variables with bivariate association P values Յ0.20 were included in the multivariable model. Multicollinearity among covariates was evaluated by assessing deviations of regression coefficients and their SEs in the fitted univariate and multivariate models, 19 and none was detected. Covariates were entered simultaneously into the model. Age-adjusted Kaplan-Meier survival curves graphically presented the relationship of the cumulative proportion of conversions to hypertension among blacks and whites. A log-rank test was used to test the homogeneity of survival curves across racial strata. 20 P values Ͻ0.05 were considered significant.
Cox proportional hazards regression was used to estimate the prognostic influence of race on conversion to hypertension, while simultaneously controlling for the confounding effect of covariates. This model estimates the instantaneous relative risk of conversion to hypertension averaged over the entire time of follow-up. The proportional hazard assumption was tested with the goodness-of-fit 2 test, which compares the observed and expected survival probabilities, and by graphic means using the log-log Kaplan-Meier curves. 21 The heterogeneity of the stratum-specific hazard ratios (HRs) between systolic BP and conversion across the various stages of diastolic BP as proposed by Breslow and Day 22 for analysis of cohort data were used. 23 Adjusted HRs and 95% CIs are reported.
Results
In this study, 18 865 individuals ( Figure 1 ) were followed through the end point of hypertension or the end point of 2550 days. Nonhypertensive subjects who met exclusion criteria except for race unknown or other than black or white (Nϭ12 868) were younger, more likely to be men, overweight, and normotensive and to have CKD and diabetes mellitus and were less likely to have normal weight and BPs (data not shown, all P values Ͻ0.01). A total of 12 045 patients (63.8%) progressed to clinical hypertension. Significant differences were identified between converters and nonconverters in all of the covariables but sex ( Table 1 ). The mean age of the cohort was 48.5 years (SD: Ϯ15.7 years), 43% were obese, and 27.4% were diabetic. Converters were significantly older than nonconverters. Table 2 shows the baseline prevalence of prehypertension in this nonhypertensive cohort. Within this cohort, 28% were normotensive, 27.2% had stage 1 prehypertension (120 to 129/80 to 84 mm Hg), and 45.2% had stage 2 prehypertension (130 to 139/85 to 89 mm Hg). 7 Significant group differences were observed in several nonmodifiable covariables with patients who were black, male, older, diabetic, and with CKD having a higher prevalence of stage 2 prehypertension. BMI was the only readily modifiable covariable examined. There was a positive linear gradient of baseline stage 2 hypertension status with increasing BMI, with the highest rate (52.4%) among grade III obesity and the lowest (25.6%) among underweight individuals. All of the patients with CKD and 72% with diabetes mellitus had stage 2 prehypertension at baseline. Table 3 summarizes results of multivariable Cox proportional hazard regression analyses and risk of conversion to hypertension over 7-year follow-up. Crude risk ratios were larger than adjusted ratios, which indicates confounding effects of covariables in the model. The overestimation eliminated by adjusting for other covariables ranged from 62.0% for CKD to 3.2% for sex. Blacks had greater risk of conversion to hypertension than whites (HR: 1.35 [95% CI: 1.30 to 1.40]) after adjusting for covariables. The strongest predictor of conversion was stage 2 systolic prehypertension followed by stage 1 systolic prehypertension. The risk of progressing to hypertension increased with advancing age. Patients who ere Ն75 years old had 46% higher risk of conversion than those aged 18 to 34 years (PϽ0.001).
Persons with stage 2 and stage 1 diastolic prehypertension had significantly elevated risk of conversion independent of other covariables. Unlike stage 2 and stage 1 systolic prehypertension, risk for conversion to hypertension did not differ between stage 2 and stage 1 diastolic prehypertension.
Compared with individuals with normal BMI (18.5 to Ͻ25 kg/m 2 ), risk of new-onset hypertension rose with increasing BMI category (Table 3) . Underweight was associated with a lower mean estimate of conversion to hypertension, although this was not statistically significant. CKD and diabetes mellitus increased risk of new-onset hypertension. Table 4 shows the empirical distribution of 9 groups of nonhypertensive individuals and risk of each group for conversion to hypertension. The largest group is composed of isolated systolic prehypertension with 20% stage 1 and 16% stage 2. Generally, the higher the stage of prehypertension, the greater was the risk of new-onset hypertension. With Table 3 . The small difference between the crude and adjusted HRs, expressed as crude/ adjusted, indicate that the degree of confounding by covariables was Ͻ4% for all 9 grades of prehypertension. The differences in crude and adjusted HRs using the 9 groups were smaller than ratios using only 3 groups, that is, normal BP, stage 1 prehypertension, and stage 2 prehypertension (Table 3) . Figure 2 shows age-adjusted Kaplan-Meier probability curves of incident hypertension (percentage remaining nonhypertensive) by race over 2550 days. The probability of blacks and whites remaining hypertension free separated during the first few months. The median conversion time [S(T) 50 ] (where S indicates survival; T, time) of blacks was 365 days earlier than whites (626 versus 991; PϽ0.001). Similarly, at the midpoint or 1250 days, 65% of blacks had already converted to hypertension compared with 54% of the whites. By end or censoring point of day 2550, Ϸ70% of blacks and 56% of whites had converted.
Discussion
The principal study finding is that black race, as recorded in the electronic health record, is associated with an accelerated risk of new-onset hypertension. Our findings are based on community practice-based electronic health record system data and included adjustments for several confounding clinical and demographic covariables. In addition to race, several other clinical characteristics were independently associated with new-onset hypertension, including age, baseline systolic and diastolic BPs, BMI, CKD, and diabetes mellitus. These findings are consonant with previous reports on risk factors in prehypertension for CVD. 10,24 -30 The dose-dependent risk of conversion noted with increasing BMI from underweight to grade III obesity is consistent with studies linking obesity and adiposity to the pathophysiology of elevated BP and hypertension. [31] [32] [33] Another novel study finding was the transadditivity of systolic and diastolic BPs when both values were examined simultaneously as predictors of new-onset hypertension (Table 4). A biological gradient of risk was observed, which corresponded with the 8 categories of prehypertension when systolic and diastolic BPs are considered simultaneously rather than the 3 separate stages of systolic and diastolic pressures. Moreover, the difference between unadjusted and adjusted crude rates was reduced when 9 rather than 3 categories of nonhypertensive systolic and diastolic BP values were considered (Table 3) . Thus, considering systolic and diastolic BPs simultaneously substantially reduces the confounding by covariables that occurs when systolic or diastolic pressures are examined separately. Although both systolic and diastolic prehypertension increase the risk of conversion to hypertension, the influence of systolic appears stronger. The stronger relationship of systolic than diastolic to cardiovascular events has also been reported, especially for people Ն50 years old. 2,34 -36 Isolated stage 1 and 2 systolic prehypertension with normal diastolic (grades 2 and 5) accounted for 36% of prehypertensive subjects in our cohort. Nearly two thirds of adults with isolated systolic prehypertension were Ն55 years of age, which is consistent with the notion that age-related arterial stiffening, 37, 38 possibly reflecting or coincident with agerelated increase in salt-sensitivity of BP, 16 contributes to prehypertension and progression to hypertension. 39 In this study, blacks had a 35% greater risk of conversion to hypertension than whites after adjustment for multiple covariables (Table 3) . Moreover, the median, age-adjusted conversion time when 50% of the group became hypertensive occurred after only Ϸ1.7 years of follow-up in blacks as compared with Ϸ2.7 years in whites (Figure 2) . The median conversion time in our study, which did not have standardized BP measurements or visits frequencies, is comparable to the 2.2 years reported for the predominantly white stage 2 prehypertensives in the Trial of Preventing Hypertension (TROPHY), a rigorous clinical trial. 3 The longer median conversion time for whites in our study than the overall TROPHY is expected, because our report included stage 1 prehypertensive and normotensive individuals. On the other hand, patients with diabetes mellitus at baseline were at greater risk for incident hypertension, and TROPHY excluded these patients.
As noted, JNC 7 recommended therapeutic lifestyle change only for most individuals with prehypertension. Although lifestyle interventions, for example, Dietary Approaches to Stop Hypertension, are efficacious in lowering BP in nonhypertensive individuals, 13 adoption in the population is limited. 15 Even in a relatively intensive clinical efficacy study (Trials of Hypertension Prevention), the relative reduction in progression to hypertension over 4 years was Ϸ15%, with an absolute reduction of 6% to 7%. 40 The relative risk reduction for de novo hypertension over 4 years was virtually identical to TROPHY patients 2 years after angiotensin receptor blockade was discontinued. 5 At 
Study Limitations
This prospective cohort study relied on data in several different electronic health record systems obtained from a variety of outpatient clinical settings in the Southeast United States. Race ascertainment was not standardized. Unlike the National Health and Nutrition Examination Surveys, BP measurements were not standardized and likely included multiple suboptimal practices. 8, 39 Unlike population studies, for example, the Framingham Heart Study, time between visits was not standardized. Of note, the Framingham report on incident hypertension was based on a single follow-up visit 4 years after baseline assessment. 5 Nonhypertensive patients excluded from the analysis for race unknown or other than black or white differed by age, sex, weight, BP category, and prevalence of diabetes and CKD. For these and other reasons, our sample and findings may not represent the broader population of nonhypertensive individuals. On the other hand, the data reflect findings in contemporary medical practice among a diverse group of clinical sites in the Southeast United States. Despite limitations, black race was associated with an accelerated transition from nonhypertensive to hypertensive status, with 50% transitioning to hypertension in only 1.7 years versus 2.7 years in whites. The finding of racial differences in progression from hypertension to prehypertension does not necessarily implicate biological differences but can include sociocultural and economic factors. 41, 42 Our study findings are potentially relevant to national health goals for reducing prevalent hypertension and improving health equity. Healthy People 2000 and 2010 included a goal to reduce the prevalence of hypertension in the US population from 29% to 16%. 8, 43, 44 Despite JNC 7 efforts to facilitate a reduction of incident hypertension by resurrecting the 1939 term "prehypertension," 1 the lifestyle-only focus in prehypertension has limited effectiveness in the population. 13, 14 Perhaps in recognizing this reality, Healthy People 2020 set a more realistic goal of reducing prevalent hypertension to 26.9% for all race groups. Even this dilutional goal is unlikely to be obtained among blacks, who had an age-adjusted hypertension prevalence of 37.9% in 2007-2008, 8 without a safe, widely adopted, and effective pharmacological intervention for slowing the rapid progression from prehypertension to hypertension. Given the excess of prevalent hypertension and related complications in blacks, 9 their accelerated transition from prehypertension to hypertension, and greater risk of CVD complications even in the absence of progression, 10 this is an opportune time for clinical effectiveness trials addressing these critical issues.
Perspectives
Public health efforts over the past 20 years, focused mainly on therapeutic lifestyle change, have not succeeded in reduc- Figure 2 . The age-adjusted probability of remaining nonhypertensive is depicted separately for black and white adults 18 to 85 years of age who were not hypertensive at time 0.
ing prevalent hypertension or racial differences in prevalent hypertension. Most hypertension progresses from the prehypertensive stage, but it was not known whether blacks with prehypertension progress to hypertension faster than whites. Our study indicates that progression to hypertension is significantly faster in blacks than whites with prehypertension. These findings raise the possibility that effective interventions in prehypertension could reduce incident hypertension and associated racial differences with longer-term potential to reduce the magnitude of prevalent hypertension and its impact on health disparities. 
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